![Diabetes Prevention and Treatment]()
The National Institute of Diabetes and Digestive and Kidney Diseases has awarded Jill Crandall, M.D., a renewal grant of $2 million over five years to extend the Diabetes Prevention Program Outcome Study (DPPOS). The original DPP study demonstrated the beneficial effects of lifestyle changes and use of metformin (a type 2 diabetes drug) in preventing or delaying the onset of type 2 diabetes (T2D) in patients at high risk for the disease. DPPOS was an 11-year follow-up study showing that long-term effects of the DPP interventions included prevention of T2D, as well as improvement in cardiovascular disease risk factors. In extending the DPPOS for another five years, Dr. Crandall and her team will examine the long-term effects of metformin treatment on cardiovascular disease and cancer. Dr. Crandall is professor of medicine and principal investigator for Einstein sites of the DPPOS, as well as a member of the DPPOS Executive Committee.
Posted on: Wednesday, March 09, 2016